What is Genalyte?
Genalyte provides an innovative on-site blood testing platform designed to deliver lab-quality results in under 30 minutes. Their flagship product, Merlin, integrates seamlessly into healthcare workflows, enabling primary care, outpatient clinics, hospitals, and government health systems to receive actionable diagnostic information while patients are still present. By automating the testing process and facilitating direct connection to electronic medical records, Genalyte effectively eliminates delays and reduces errors associated with traditional laboratory testing, ensuring prompt communication of critical health data.
How much funding has Genalyte raised?
Genalyte has raised a total of $141.8M across 4 funding rounds:
Series B
$11.8M
Series C
$44M
Private Equity
$36M
Unspecified
$50M
Series B (2012): $11.8M with participation from Claremont Creek Ventures
Series C (2015): $44M led by Khosla Ventures, Claremont Creek Ventures, and Redmile Group
Private Equity (2016): $36M supported by Khosla Ventures and Redmile Group
Unspecified (2021): $50M featuring Samsara Networks, Inc, Redmile Group , LLC, HBM Partners AG, Provenio Capital, Khosla Ventures, and Verily
Key Investors in Genalyte
Khosla Ventures
Khosla Ventures is a venture capital firm specializing in breakthrough technologies, with a broad investment focus including consumer, enterprise, AI, fintech, semiconductors, health, agriculture, sustainable energy, and robotics.
Claremont Creek Ventures
Claremont Creek Ventures is an early-stage venture firm with deep domain expertise in information technology, particularly digital healthcare, energy technology, and online businesses.
Redmile Group
Redmile Group LLC operates within the Venture Capital & Private Equity industry, based in New York City.
What's next for Genalyte?
The substantial enterprise-level funding and recent strategic investment position Genalyte for significant scaling and market penetration. With a focus on enhancing diagnostic efficiency, the company is poised to further develop its technology and expand its reach within the healthcare sector. Future growth will likely involve strengthening partnerships with healthcare providers and potentially exploring new applications for its rapid testing platform. The backing from prominent investors suggests confidence in Genalyte's ability to disrupt traditional diagnostic workflows and improve patient care outcomes.
See full Genalyte company page
